Search the GHTC website

Global health R&D delivers for Minnesota

US government investment in global health R&D has delivered

Amount
$161.5 million
to Minnesota research institutions
Jobs
2,000+ new jobs
for Minnesota
Minnesota's top USG-funded global health R&D institutions

Minnesota's top USG-funded global health R&D institutions

University of Minnesota (including the Uganda Research Training Collaborative)
$138.8 million
Mayo Clinic (including Mayo Medical School)
$18.2 million
MarPam Pharma
$2.5 million
Hennepin Healthcare Research Institute
$763 thousand
HealthPartners Institute
$619 thousand
Sersense Inc
$262 thousand
GRIP Molecular
$177 thousand
3M
$150 thousand

Minnesota's top areas of global health R&D by USG funding

7.3%
Arenaviral hemorrhagic fevers (including Lassa fever)
6.4%
COVID-19
5.6%
Cryptococcal meningitis
2.7%
Diarrheal diseases
4%
Flioviral diseases (including Ebola, Marburg)
23.8%
HIV/AIDS
9.4%
Malaria
2.5%
Neglected tropical diseases
Dengue
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
7.4%
Reproductive health
8.8%
Salmonella infections
13.5%
Tuberculosis
5.2%
Zika
3.2%
Other
Bacterial pneumonia & meningitis
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Global health R&D at work in Minnesota

Scientists at the University of Minnesota Medical School are working to unlock why antiretroviral therapies are unable to completely shut down HIV production in cells in certain parts of the body in the hopes of advancing effective solutions. Their research found that nearly 99 percent of these HIV-infected cells are found in tissue in the lymph nodes, spleen, and gastrointestinal tract. This reservoir of latently infected cells can reactivate if therapy is interrupted, posing a major challenge to curing the disease. The researchers are now exploring whether there are drugs that can be used to “reactivate” the virus from latent cells, allowing antiretrovirals to then attack and eliminate it. These discoveries could lead to the development of more effective treatments for HIV or even a cure for AIDS. Globally, more than 38 million people are living with HIV.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: USAID/Oris Chimenya